| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 45 | 2024 | 167 | 9.550 |
Why?
|
| Patient Readmission | 14 | 2026 | 161 | 3.330 |
Why?
|
| Aged | 96 | 2026 | 5901 | 3.270 |
Why?
|
| Humans | 144 | 2026 | 16832 | 3.010 |
Why?
|
| Male | 104 | 2026 | 9556 | 2.970 |
Why?
|
| Patient Discharge | 11 | 2023 | 152 | 2.880 |
Why?
|
| Female | 106 | 2026 | 12193 | 2.670 |
Why?
|
| Exercise Therapy | 13 | 2019 | 71 | 2.620 |
Why?
|
| Transitional Care | 6 | 2024 | 16 | 2.590 |
Why?
|
| Heart Failure | 6 | 2026 | 403 | 2.520 |
Why?
|
| Self Care | 14 | 2017 | 139 | 2.470 |
Why?
|
| Quality of Life | 25 | 2022 | 477 | 2.330 |
Why?
|
| Home Care Services | 4 | 2026 | 35 | 2.300 |
Why?
|
| Middle Aged | 72 | 2026 | 7515 | 2.280 |
Why?
|
| Exercise | 12 | 2020 | 513 | 2.270 |
Why?
|
| Influenza, Human | 10 | 2025 | 292 | 2.240 |
Why?
|
| Internet | 14 | 2016 | 207 | 2.200 |
Why?
|
| Walking | 13 | 2019 | 82 | 2.030 |
Why?
|
| Dyspnea | 16 | 2018 | 45 | 2.020 |
Why?
|
| Hospitalization | 17 | 2026 | 816 | 2.000 |
Why?
|
| Aged, 80 and over | 32 | 2026 | 1887 | 1.960 |
Why?
|
| Dementia | 5 | 2024 | 137 | 1.940 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2024 | 515 | 1.930 |
Why?
|
| Adult | 43 | 2026 | 7255 | 1.590 |
Why?
|
| Rural Population | 6 | 2025 | 58 | 1.580 |
Why?
|
| Influenza Vaccines | 6 | 2025 | 300 | 1.540 |
Why?
|
| United States | 34 | 2026 | 3858 | 1.490 |
Why?
|
| Antibodies, Viral | 4 | 2026 | 70 | 1.480 |
Why?
|
| Retrospective Studies | 19 | 2026 | 2463 | 1.400 |
Why?
|
| Vietnam | 22 | 2022 | 42 | 1.310 |
Why?
|
| Adolescent | 28 | 2026 | 3464 | 1.300 |
Why?
|
| Young Adult | 22 | 2026 | 2456 | 1.220 |
Why?
|
| Telemedicine | 5 | 2024 | 190 | 1.210 |
Why?
|
| Health Education | 7 | 2019 | 79 | 1.190 |
Why?
|
| Anxiety | 9 | 2021 | 154 | 1.150 |
Why?
|
| Medicare | 9 | 2021 | 188 | 1.130 |
Why?
|
| Mentoring | 2 | 2019 | 29 | 1.120 |
Why?
|
| Motor Activity | 5 | 2015 | 196 | 1.110 |
Why?
|
| Social Support | 8 | 2019 | 195 | 1.090 |
Why?
|
| Depression | 11 | 2021 | 479 | 1.080 |
Why?
|
| Medicare Part C | 2 | 2023 | 11 | 1.040 |
Why?
|
| Pandemics | 4 | 2024 | 289 | 1.030 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 145 | 1.010 |
Why?
|
| Disease Progression | 6 | 2020 | 252 | 1.010 |
Why?
|
| Hospitals | 6 | 2022 | 69 | 0.940 |
Why?
|
| Patient Education as Topic | 7 | 2015 | 186 | 0.940 |
Why?
|
| Family Characteristics | 8 | 2026 | 69 | 0.920 |
Why?
|
| Time Factors | 12 | 2026 | 989 | 0.910 |
Why?
|
| Metapneumovirus | 1 | 2025 | 7 | 0.900 |
Why?
|
| Paramyxoviridae Infections | 1 | 2025 | 8 | 0.900 |
Why?
|
| Prospective Studies | 19 | 2026 | 1186 | 0.900 |
Why?
|
| Health Care Costs | 4 | 2019 | 192 | 0.890 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2025 | 352 | 0.890 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 58 | 0.860 |
Why?
|
| Aftercare | 3 | 2022 | 46 | 0.850 |
Why?
|
| Cross-Sectional Studies | 20 | 2026 | 1233 | 0.840 |
Why?
|
| Terminal Care | 3 | 2026 | 48 | 0.840 |
Why?
|
| Child, Preschool | 14 | 2026 | 1430 | 0.840 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 51 | 0.830 |
Why?
|
| Fitness Centers | 3 | 2008 | 10 | 0.820 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 393 | 0.820 |
Why?
|
| Caregivers | 6 | 2022 | 132 | 0.810 |
Why?
|
| Palliative Care | 3 | 2021 | 53 | 0.800 |
Why?
|
| Child | 17 | 2026 | 2433 | 0.800 |
Why?
|
| Outpatients | 3 | 2021 | 99 | 0.790 |
Why?
|
| Surveys and Questionnaires | 16 | 2021 | 1204 | 0.760 |
Why?
|
| Risk Assessment | 7 | 2026 | 1047 | 0.740 |
Why?
|
| California | 9 | 2026 | 2244 | 0.740 |
Why?
|
| Self Report | 3 | 2020 | 248 | 0.720 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 141 | 0.700 |
Why?
|
| Skilled Nursing Facilities | 2 | 2021 | 6 | 0.690 |
Why?
|
| Decision Making | 2 | 2025 | 164 | 0.690 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 185 | 0.680 |
Why?
|
| Treatment Outcome | 14 | 2024 | 1098 | 0.670 |
Why?
|
| Unemployment | 1 | 2020 | 12 | 0.660 |
Why?
|
| Vaccination | 8 | 2025 | 725 | 0.660 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 229 | 0.650 |
Why?
|
| Patient Transfer | 4 | 2021 | 25 | 0.640 |
Why?
|
| Employment | 1 | 2020 | 38 | 0.640 |
Why?
|
| Monitoring, Ambulatory | 3 | 2011 | 17 | 0.640 |
Why?
|
| Incidence | 6 | 2025 | 1229 | 0.620 |
Why?
|
| Infant | 9 | 2026 | 1212 | 0.610 |
Why?
|
| House Calls | 1 | 2019 | 9 | 0.600 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2019 | 6 | 0.600 |
Why?
|
| Cohort Studies | 8 | 2025 | 2396 | 0.600 |
Why?
|
| Seasons | 5 | 2025 | 114 | 0.590 |
Why?
|
| Severity of Illness Index | 12 | 2021 | 410 | 0.590 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2024 | 63 | 0.590 |
Why?
|
| Risk Factors | 13 | 2025 | 3108 | 0.590 |
Why?
|
| Accelerometry | 4 | 2019 | 48 | 0.590 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 1058 | 0.580 |
Why?
|
| Community Participation | 1 | 2019 | 29 | 0.570 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2025 | 21 | 0.550 |
Why?
|
| Longitudinal Studies | 12 | 2022 | 653 | 0.550 |
Why?
|
| Suicide, Assisted | 1 | 2018 | 4 | 0.540 |
Why?
|
| Policy Making | 1 | 2018 | 14 | 0.540 |
Why?
|
| Terminally Ill | 1 | 2018 | 9 | 0.540 |
Why?
|
| Community Health Services | 3 | 2017 | 68 | 0.530 |
Why?
|
| Cell Phone | 2 | 2009 | 9 | 0.530 |
Why?
|
| Managed Care Programs | 3 | 2008 | 275 | 0.520 |
Why?
|
| Cost of Illness | 4 | 2026 | 90 | 0.520 |
Why?
|
| Health Policy | 1 | 2018 | 101 | 0.510 |
Why?
|
| Biomarkers | 2 | 2024 | 284 | 0.510 |
Why?
|
| Insurance Coverage | 1 | 2018 | 102 | 0.510 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 130 | 0.510 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 137 | 0.500 |
Why?
|
| Pilot Projects | 9 | 2018 | 210 | 0.490 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 40 | 0.490 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 51 | 0.480 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2025 | 56 | 0.480 |
Why?
|
| Smartphone | 3 | 2021 | 10 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 311 | 0.480 |
Why?
|
| Activities of Daily Living | 6 | 2009 | 71 | 0.480 |
Why?
|
| Prevalence | 12 | 2025 | 785 | 0.470 |
Why?
|
| Inpatients | 1 | 2016 | 78 | 0.470 |
Why?
|
| Health Behavior | 4 | 2012 | 332 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 317 | 0.470 |
Why?
|
| Physical Fitness | 4 | 2016 | 65 | 0.450 |
Why?
|
| Self Efficacy | 6 | 2015 | 68 | 0.450 |
Why?
|
| Postural Balance | 2 | 2014 | 12 | 0.450 |
Why?
|
| Acute Disease | 2 | 2026 | 144 | 0.450 |
Why?
|
| Virus Shedding | 2 | 2026 | 2 | 0.440 |
Why?
|
| Unsafe Sex | 1 | 2015 | 19 | 0.430 |
Why?
|
| Vaccines, Inactivated | 2 | 2025 | 73 | 0.430 |
Why?
|
| Sexual and Gender Minorities | 1 | 2015 | 32 | 0.420 |
Why?
|
| Risk-Taking | 1 | 2015 | 92 | 0.420 |
Why?
|
| Child Abuse | 2 | 2018 | 44 | 0.410 |
Why?
|
| Logistic Models | 6 | 2019 | 796 | 0.410 |
Why?
|
| Case-Control Studies | 5 | 2018 | 995 | 0.400 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 268 | 0.390 |
Why?
|
| Wisconsin | 4 | 2025 | 12 | 0.380 |
Why?
|
| Mental Health | 3 | 2014 | 161 | 0.380 |
Why?
|
| Disability Evaluation | 3 | 2014 | 38 | 0.370 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 23 | 0.370 |
Why?
|
| Patient Compliance | 2 | 2016 | 262 | 0.360 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 346 | 0.360 |
Why?
|
| Recreation | 1 | 2012 | 38 | 0.360 |
Why?
|
| Ambulatory Care | 2 | 2026 | 205 | 0.350 |
Why?
|
| Patient Selection | 3 | 2018 | 175 | 0.350 |
Why?
|
| Gait | 1 | 2011 | 8 | 0.350 |
Why?
|
| Video Games | 1 | 2011 | 9 | 0.350 |
Why?
|
| Postmenopause | 1 | 2012 | 243 | 0.340 |
Why?
|
| Nursing Informatics | 2 | 2010 | 2 | 0.340 |
Why?
|
| Affect | 3 | 2012 | 21 | 0.340 |
Why?
|
| Influenza B virus | 3 | 2025 | 13 | 0.340 |
Why?
|
| Ergometry | 1 | 2011 | 2 | 0.330 |
Why?
|
| Electronic Health Records | 3 | 2024 | 702 | 0.330 |
Why?
|
| Feedback, Psychological | 2 | 2015 | 6 | 0.330 |
Why?
|
| Faculty, Nursing | 1 | 2010 | 3 | 0.330 |
Why?
|
| Inservice Training | 1 | 2010 | 11 | 0.330 |
Why?
|
| Nursing Staff, Hospital | 2 | 2021 | 10 | 0.320 |
Why?
|
| Patient Participation | 3 | 2011 | 120 | 0.320 |
Why?
|
| Veterans | 4 | 2022 | 143 | 0.320 |
Why?
|
| Needs Assessment | 1 | 2010 | 64 | 0.320 |
Why?
|
| Health Promotion | 3 | 2008 | 277 | 0.320 |
Why?
|
| Advance Care Planning | 1 | 2010 | 22 | 0.320 |
Why?
|
| Regression Analysis | 3 | 2020 | 261 | 0.320 |
Why?
|
| Frailty | 2 | 2020 | 13 | 0.310 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 61 | 0.310 |
Why?
|
| Reinforcement (Psychology) | 1 | 2009 | 2 | 0.300 |
Why?
|
| Stress, Psychological | 2 | 2021 | 136 | 0.300 |
Why?
|
| Sex Factors | 6 | 2016 | 560 | 0.300 |
Why?
|
| Health Services for the Aged | 2 | 2014 | 14 | 0.300 |
Why?
|
| Delivery of Health Care | 4 | 2016 | 374 | 0.300 |
Why?
|
| Washington | 5 | 2019 | 376 | 0.300 |
Why?
|
| Feasibility Studies | 5 | 2018 | 108 | 0.300 |
Why?
|
| Self Concept | 1 | 2009 | 36 | 0.300 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 571 | 0.290 |
Why?
|
| Communication | 1 | 2010 | 183 | 0.290 |
Why?
|
| Exercise Test | 6 | 2015 | 36 | 0.290 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 6 | 0.290 |
Why?
|
| Patient Satisfaction | 4 | 2012 | 186 | 0.290 |
Why?
|
| Insurance Benefits | 2 | 2008 | 12 | 0.290 |
Why?
|
| Cell Culture Techniques | 2 | 2025 | 5 | 0.280 |
Why?
|
| Mortality | 2 | 2026 | 116 | 0.280 |
Why?
|
| Forced Expiratory Volume | 5 | 2017 | 59 | 0.280 |
Why?
|
| Self-Assessment | 1 | 2007 | 14 | 0.260 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 6 | 0.260 |
Why?
|
| Quality of Health Care | 2 | 2021 | 249 | 0.250 |
Why?
|
| Health Status | 4 | 2013 | 256 | 0.250 |
Why?
|
| Accidental Falls | 2 | 2020 | 49 | 0.250 |
Why?
|
| Qualitative Research | 5 | 2025 | 288 | 0.250 |
Why?
|
| Survival Rate | 3 | 2017 | 247 | 0.250 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 445 | 0.250 |
Why?
|
| Peptides | 2 | 2018 | 14 | 0.250 |
Why?
|
| Body Mass Index | 2 | 2024 | 925 | 0.240 |
Why?
|
| Mumps virus | 1 | 2026 | 2 | 0.240 |
Why?
|
| Prognosis | 5 | 2026 | 568 | 0.240 |
Why?
|
| Propensity Score | 1 | 2026 | 78 | 0.230 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 84 | 0.230 |
Why?
|
| Mumps | 1 | 2026 | 13 | 0.230 |
Why?
|
| Hand Strength | 3 | 2020 | 12 | 0.230 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2026 | 64 | 0.230 |
Why?
|
| Cough | 2 | 2015 | 20 | 0.230 |
Why?
|
| Seroepidemiologic Studies | 1 | 2025 | 18 | 0.230 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2025 | 6 | 0.220 |
Why?
|
| Antiviral Agents | 1 | 2026 | 92 | 0.220 |
Why?
|
| Mass Vaccination | 1 | 2005 | 22 | 0.220 |
Why?
|
| Salmonella | 1 | 2024 | 2 | 0.220 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2024 | 5 | 0.220 |
Why?
|
| Shigella | 1 | 2024 | 2 | 0.220 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 7 | 0.220 |
Why?
|
| Pain | 3 | 2024 | 65 | 0.210 |
Why?
|
| Chickenpox | 1 | 2005 | 35 | 0.210 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2024 | 8 | 0.210 |
Why?
|
| Antigens, Viral | 1 | 2024 | 4 | 0.210 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 39 | 0.210 |
Why?
|
| Fatigue | 3 | 2024 | 30 | 0.210 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 91 | 0.210 |
Why?
|
| Quality Improvement | 2 | 2016 | 184 | 0.210 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 27 | 0.210 |
Why?
|
| Cardiac Rehabilitation | 1 | 2004 | 8 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2024 | 290 | 0.210 |
Why?
|
| Interleukin-8 | 1 | 2024 | 4 | 0.200 |
Why?
|
| Hyperkalemia | 1 | 2024 | 14 | 0.200 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 113 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 489 | 0.200 |
Why?
|
| Frail Elderly | 2 | 2020 | 9 | 0.190 |
Why?
|
| Family | 2 | 2021 | 99 | 0.190 |
Why?
|
| Registries | 3 | 2018 | 449 | 0.190 |
Why?
|
| Walk Test | 2 | 2019 | 5 | 0.180 |
Why?
|
| Suicidal Ideation | 2 | 2014 | 98 | 0.180 |
Why?
|
| Age Factors | 3 | 2016 | 814 | 0.180 |
Why?
|
| Brain Concussion | 1 | 2022 | 1 | 0.180 |
Why?
|
| Motivation | 3 | 2021 | 103 | 0.180 |
Why?
|
| Outcome Assessment (Health Care) | 4 | 2015 | 199 | 0.180 |
Why?
|
| Interviews as Topic | 2 | 2025 | 305 | 0.180 |
Why?
|
| Comorbidity | 4 | 2022 | 516 | 0.180 |
Why?
|
| Military Personnel | 1 | 2022 | 13 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 353 | 0.170 |
Why?
|
| Bayes Theorem | 3 | 2026 | 75 | 0.170 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 70 | 0.170 |
Why?
|
| Fear | 1 | 2021 | 14 | 0.170 |
Why?
|
| Monitoring, Physiologic | 2 | 2015 | 35 | 0.170 |
Why?
|
| Work Engagement | 1 | 2021 | 2 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 657 | 0.170 |
Why?
|
| Primary Health Care | 2 | 2024 | 693 | 0.160 |
Why?
|
| HIV Infections | 2 | 2018 | 708 | 0.160 |
Why?
|
| Yoga | 2 | 2012 | 25 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 197 | 0.160 |
Why?
|
| Walking Speed | 1 | 2020 | 3 | 0.160 |
Why?
|
| Health Personnel | 2 | 2019 | 132 | 0.160 |
Why?
|
| Telephone | 1 | 2021 | 157 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2020 | 13 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 41 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 38 | 0.160 |
Why?
|
| Inflammation | 2 | 2018 | 56 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2020 | 211 | 0.150 |
Why?
|
| Telomere | 1 | 2019 | 16 | 0.150 |
Why?
|
| Chronic Pain | 1 | 2021 | 125 | 0.150 |
Why?
|
| Independent Living | 1 | 2019 | 24 | 0.150 |
Why?
|
| Geriatric Nursing | 1 | 2019 | 3 | 0.150 |
Why?
|
| Attitude to Death | 1 | 2019 | 7 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2016 | 100 | 0.150 |
Why?
|
| Occupational Stress | 1 | 2019 | 3 | 0.150 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2019 | 10 | 0.150 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 3 | 2005 | 3 | 0.150 |
Why?
|
| Oregon | 1 | 2019 | 168 | 0.150 |
Why?
|
| Occupational Diseases | 1 | 2019 | 33 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 106 | 0.140 |
Why?
|
| Bronchodilator Agents | 2 | 2016 | 21 | 0.140 |
Why?
|
| State Medicine | 1 | 2018 | 4 | 0.140 |
Why?
|
| Spouses | 1 | 2019 | 9 | 0.140 |
Why?
|
| Reference Values | 3 | 2007 | 78 | 0.140 |
Why?
|
| Papillomaviridae | 1 | 2019 | 58 | 0.140 |
Why?
|
| Spirometry | 2 | 2015 | 53 | 0.140 |
Why?
|
| Singing | 1 | 2018 | 1 | 0.140 |
Why?
|
| Cyclohexylamines | 1 | 2018 | 1 | 0.140 |
Why?
|
| Ornithine | 1 | 2018 | 1 | 0.140 |
Why?
|
| Personal Autonomy | 1 | 2018 | 6 | 0.140 |
Why?
|
| Psychotherapy | 1 | 2018 | 55 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 9 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 24 | 0.130 |
Why?
|
| Actigraphy | 3 | 2015 | 14 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2018 | 72 | 0.130 |
Why?
|
| Environment Design | 2 | 2020 | 65 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 55 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 26 | 0.130 |
Why?
|
| Abbreviated Injury Scale | 1 | 2016 | 1 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2018 | 142 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2016 | 9 | 0.130 |
Why?
|
| Trauma Centers | 1 | 2016 | 6 | 0.130 |
Why?
|
| Psychology, Adolescent | 1 | 2016 | 11 | 0.120 |
Why?
|
| Learning | 1 | 2016 | 18 | 0.120 |
Why?
|
| Medical Overuse | 1 | 2016 | 14 | 0.120 |
Why?
|
| Violence | 1 | 2016 | 32 | 0.120 |
Why?
|
| Crime Victims | 1 | 2016 | 25 | 0.120 |
Why?
|
| Sinusitis | 1 | 2016 | 18 | 0.120 |
Why?
|
| Metered Dose Inhalers | 1 | 2016 | 4 | 0.120 |
Why?
|
| Prescription Drug Overuse | 1 | 2016 | 4 | 0.120 |
Why?
|
| Age Distribution | 2 | 2015 | 221 | 0.120 |
Why?
|
| Lung | 1 | 2016 | 52 | 0.120 |
Why?
|
| Students | 1 | 2016 | 49 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2016 | 32 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 94 | 0.120 |
Why?
|
| Length of Stay | 1 | 2016 | 169 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 189 | 0.120 |
Why?
|
| Self-Management | 1 | 2016 | 25 | 0.120 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 19 | 0.120 |
Why?
|
| Research Report | 1 | 2015 | 23 | 0.120 |
Why?
|
| Research | 2 | 2016 | 53 | 0.110 |
Why?
|
| Health Services Research | 1 | 2016 | 180 | 0.110 |
Why?
|
| Public Sector | 1 | 2015 | 6 | 0.110 |
Why?
|
| Habits | 1 | 2015 | 6 | 0.110 |
Why?
|
| Capacity Building | 1 | 2015 | 9 | 0.110 |
Why?
|
| Somatoform Disorders | 1 | 2015 | 6 | 0.110 |
Why?
|
| Tics | 1 | 2015 | 3 | 0.110 |
Why?
|
| Diazomethane | 1 | 2015 | 1 | 0.110 |
Why?
|
| Methionine | 1 | 2015 | 5 | 0.110 |
Why?
|
| Smoking | 1 | 2017 | 373 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 2 | 2026 | 13 | 0.110 |
Why?
|
| Child Abuse, Sexual | 2 | 2018 | 13 | 0.110 |
Why?
|
| Immunization, Secondary | 2 | 2026 | 58 | 0.110 |
Why?
|
| Respiratory Function Tests | 2 | 2012 | 26 | 0.110 |
Why?
|
| Residence Characteristics | 2 | 2016 | 244 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2016 | 25 | 0.110 |
Why?
|
| Antibody Formation | 2 | 2024 | 7 | 0.100 |
Why?
|
| Research Design | 4 | 2018 | 319 | 0.100 |
Why?
|
| Hospice Care | 1 | 2013 | 9 | 0.100 |
Why?
|
| Exercise Tolerance | 2 | 2019 | 10 | 0.090 |
Why?
|
| Physical Endurance | 1 | 2012 | 4 | 0.090 |
Why?
|
| Pain Management | 1 | 2013 | 56 | 0.090 |
Why?
|
| Vital Capacity | 1 | 2012 | 33 | 0.090 |
Why?
|
| Focus Groups | 3 | 2018 | 140 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2016 | 382 | 0.090 |
Why?
|
| Guanylate Cyclase | 2 | 2002 | 2 | 0.090 |
Why?
|
| Expert Testimony | 1 | 2011 | 4 | 0.090 |
Why?
|
| Geriatrics | 1 | 2011 | 5 | 0.090 |
Why?
|
| Observational Studies as Topic | 2 | 2024 | 44 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 291 | 0.090 |
Why?
|
| Patient Simulation | 1 | 2010 | 1 | 0.080 |
Why?
|
| Telenursing | 1 | 2010 | 1 | 0.080 |
Why?
|
| Manikins | 1 | 2010 | 2 | 0.080 |
Why?
|
| Research Personnel | 2 | 2021 | 24 | 0.080 |
Why?
|
| Education, Distance | 1 | 2010 | 5 | 0.080 |
Why?
|
| Psychometrics | 2 | 2021 | 114 | 0.080 |
Why?
|
| Factor Analysis, Statistical | 2 | 2018 | 34 | 0.080 |
Why?
|
| Life Style | 1 | 2012 | 305 | 0.080 |
Why?
|
| Attitude to Computers | 1 | 2010 | 13 | 0.080 |
Why?
|
| Probability | 2 | 2007 | 66 | 0.080 |
Why?
|
| Aging | 1 | 2011 | 146 | 0.080 |
Why?
|
| Family Relations | 1 | 2009 | 15 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2009 | 21 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2012 | 248 | 0.070 |
Why?
|
| Health Surveys | 3 | 2016 | 226 | 0.070 |
Why?
|
| Cost Savings | 1 | 2007 | 20 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 207 | 0.060 |
Why?
|
| Models, Molecular | 2 | 2018 | 2 | 0.060 |
Why?
|
| Consumer Behavior | 1 | 2007 | 27 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 2 | 2018 | 82 | 0.060 |
Why?
|
| Antibody Affinity | 1 | 2026 | 1 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2026 | 33 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2005 | 12 | 0.060 |
Why?
|
| Genotype | 1 | 2026 | 198 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2026 | 81 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 36 | 0.060 |
Why?
|
| Contact Tracing | 1 | 2025 | 2 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 1 | 0.060 |
Why?
|
| Tyrosine | 1 | 2005 | 2 | 0.060 |
Why?
|
| Minnesota | 1 | 2025 | 51 | 0.060 |
Why?
|
| Measles | 1 | 2005 | 25 | 0.060 |
Why?
|
| Health Maintenance Organizations | 1 | 2007 | 358 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 160 | 0.060 |
Why?
|
| Basic Reproduction Number | 1 | 2025 | 1 | 0.060 |
Why?
|
| Access to Information | 1 | 2005 | 11 | 0.050 |
Why?
|
| Tennessee | 1 | 2024 | 6 | 0.050 |
Why?
|
| Linear Models | 2 | 2016 | 187 | 0.050 |
Why?
|
| Urban Population | 1 | 2025 | 105 | 0.050 |
Why?
|
| Computers, Handheld | 1 | 2024 | 10 | 0.050 |
Why?
|
| Eggs | 1 | 2024 | 8 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2024 | 20 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 14 | 0.050 |
Why?
|
| Spironolactone | 1 | 2024 | 7 | 0.050 |
Why?
|
| Cause of Death | 1 | 2005 | 171 | 0.050 |
Why?
|
| Peer Group | 1 | 2004 | 50 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2024 | 52 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 1 | 0.050 |
Why?
|
| Online Systems | 1 | 2003 | 7 | 0.050 |
Why?
|
| Continental Population Groups | 2 | 2016 | 255 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2024 | 110 | 0.050 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 2 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 76 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 114 | 0.040 |
Why?
|
| Nurses | 1 | 2021 | 32 | 0.040 |
Why?
|
| Government Programs | 1 | 2020 | 11 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 33 | 0.040 |
Why?
|
| Health Priorities | 1 | 2020 | 21 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 54 | 0.040 |
Why?
|
| Kinetics | 2 | 2015 | 12 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 149 | 0.040 |
Why?
|
| Health Resources | 1 | 2018 | 35 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 811 | 0.030 |
Why?
|
| Scotland | 1 | 2018 | 3 | 0.030 |
Why?
|
| Physical Abuse | 1 | 2018 | 2 | 0.030 |
Why?
|
| Respiration | 1 | 2018 | 5 | 0.030 |
Why?
|
| Electrons | 1 | 2018 | 1 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2018 | 2 | 0.030 |
Why?
|
| Hydrogen | 1 | 2018 | 3 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 6 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 10 | 0.030 |
Why?
|
| Memory | 1 | 2018 | 13 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 32 | 0.030 |
Why?
|
| Amino Acids | 1 | 2018 | 5 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2018 | 35 | 0.030 |
Why?
|
| Bortezomib | 1 | 2017 | 1 | 0.030 |
Why?
|
| Melphalan | 1 | 2017 | 2 | 0.030 |
Why?
|
| Prednisone | 1 | 2017 | 5 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 19 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 54 | 0.030 |
Why?
|
| Infection | 1 | 2017 | 17 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 110 | 0.030 |
Why?
|
| Cognition | 1 | 2018 | 90 | 0.030 |
Why?
|
| Time | 1 | 2016 | 16 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2016 | 11 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 19 | 0.030 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 4 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 39 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2015 | 34 | 0.030 |
Why?
|
| Nuclear Family | 1 | 2015 | 7 | 0.030 |
Why?
|
| Medical Assistance | 1 | 2015 | 7 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 22 | 0.030 |
Why?
|
| Photolysis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Minority Groups | 1 | 2016 | 99 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 6 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 569 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2015 | 107 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 129 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2005 | 2 | 0.030 |
Why?
|
| Protein Transport | 2 | 2005 | 2 | 0.030 |
Why?
|
| Cell Line | 2 | 2005 | 9 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 325 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 235 | 0.020 |
Why?
|
| Americas | 1 | 2013 | 2 | 0.020 |
Why?
|
| Northwestern United States | 1 | 2013 | 53 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2016 | 418 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 163 | 0.020 |
Why?
|
| Transfection | 2 | 2002 | 3 | 0.020 |
Why?
|
| Loneliness | 1 | 2012 | 9 | 0.020 |
Why?
|
| Consensus | 1 | 2011 | 40 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2010 | 11 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2009 | 6 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 84 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 12 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 33 | 0.020 |
Why?
|
| Neoplasms | 1 | 2013 | 447 | 0.020 |
Why?
|
| Pacific Islands | 1 | 2005 | 6 | 0.010 |
Why?
|
| Immunity, Herd | 1 | 2005 | 4 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 36 | 0.010 |
Why?
|
| Transportation | 1 | 2005 | 12 | 0.010 |
Why?
|
| Measles Vaccine | 1 | 2005 | 17 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2005 | 35 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2005 | 25 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 1 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 86 | 0.010 |
Why?
|
| Schools | 1 | 2005 | 91 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 828 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 2002 | 1 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 1 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2002 | 2 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 5 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 12 | 0.010 |
Why?
|
| Autopsy | 1 | 2002 | 16 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 29 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2001 | 1 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 2 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 5 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 7 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 16 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 33 | 0.010 |
Why?
|
| Temperature | 1 | 2001 | 18 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 26 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 110 | 0.010 |
Why?
|
| Animals | 1 | 2001 | 237 | 0.010 |
Why?
|